Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Cancers, Rago (Novartis): "Turn to Improve Quality of Life Patients with Lmc"

Summary by Il Tempo
Rome, 16 Sep. (AdnKronos Salute) - "The therapeutic innovation has allowed to change the history" of chronic myeloid leukemia (Lmc) "and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the context of Lmc, wants to deal with the listening of the needs of patients, especially as regards their quality of life. Marco Rago, Medical…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

10 Articles

We have created a very simple digital tool, called Vita Lmc Tracker, which serves patients to monitor the signs and symptoms of the disease and bring this information into the study of their doctor, so that they can have a more informed medical-patient discussion. Marco Rago, Medical Head Oncology Novartis Italia, told us, at the meeting with the press, promoted by the pharmaceutical in Milan on chronic myeloid leukaemia, live with, listen to, p…

·Bologna, Italy
Read Full Article

(Adnkronos) "The therapeutic innovation has allowed to change the history" of chronic myeloid leukemia (Lmc) "and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the Lmc, wants to deal with listening to the needs of patients, especially as regards [...]

(Adnkronos) therapeutic innovation has made it possible to change the history of chronic myeloid leukaemia (Lmc) and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the Lmc, wants to deal with listening to the needs of patients, especially as regards the [...] L'articolo Tumori, Rago (Novartis): "Impegnati a migliori qualità v…

(Adnkronos) - Today we have therapies for the treatment of chronic myeloid leukaemia (Lmc) that seem to be very well tolerated and,

Il TempoIl Tempo
+4 Reposted by 4 other sources

Rome, 16 Sep. (AdnKronos Salute) - "The therapeutic innovation has allowed to change the history" of chronic myeloid leukemia (Lmc) "and to achieve a very high survival. Alongside the scientific component of research and development, Novartis, engaged for about 30 years in oncoematology, in particular in the context of Lmc, wants to deal with the listening of the needs of patients, especially as regards their quality of life. Marco Rago, Medical…

·Rome, Italy
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Il Tempo broke the news in Rome, Italy on Wednesday, September 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal